Zobrazeno 1 - 10
of 612
pro vyhledávání: '"H, Riehm"'
Publikováno v:
Klinische Pädiatrie. 225:S16-S29
During the last 6 years 73 previously untreated children and adolescents with acute lymphoblastic leukemia were enrolled on a non-randomized therapy protocol. In this longitudinal study the specific accent was put on the intensified induction treatme
Treatment Trial with Recombinant Human Erythropoietin in Children with Congenital Hypoplastic Anemia
Autor:
H. Riehm, S Sauter, G Trenn, Alfred Reiter, I Meier, K. U. Eckhardt, Charlotte M. Niemeyer, J. Holldack, E Baumgarten, A. Jobke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc6244fe8f6da277f98d1774f344bed0
https://doi.org/10.1159/000419537
https://doi.org/10.1159/000419537
Autor:
Yinmei Zhou, Martin Schrappe, Ching-Hon Pui, Giuseppe Masera, Lewis B. Silverman, M. G. Valsecchi, William E. Evans, S Richards, Susana C. Raimondi, Nyla A. Heerema, Etienne Vilmer, Andrea Biondi, André Baruchel, Bruce M. Camitta, Jeanette Pullen, G. E. Janka-Schaub, Harland Sather, Christine J. Harrison, Jonathan J. Shuster, Stephen E. Sallan, Jochen Harbott, JM Chessells, D. Harms, Willem Kamps, Helmut Gadner, Paul S. Gaynon, Patricia L. Harrison, OB Eden, H. Riehm, James M. Boyett, Andrew J. Carroll
Publikováno v:
Leukemia, 17(4), 700-706. Nature Publishing Group
To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single
Publikováno v:
Klinische Pädiatrie. 213:169-174
One of the strongest predictive factors for therapy outcome in childhood acute lymphoblastic leukaemia (ALL), treated according to ALL-BFM protocols, is the response to initial prednisone treatment. Prednisone response is characterized by the periphe
Autor:
Günter Henze, H. Riehm, Helmut Gadner, B. Kornhuber, Werner Havers, C. Urban, H. Plüss, U. Bode, Felix Zintl, Joachim Kühl, Martin Schrappe, Ch. Niemeyer, A. Reiter, Dietrich Niethammer, J. Ritter
Publikováno v:
Klinische Pädiatrie. 210:192-199
Background The introduction of cranial radiotherapy (CRT) has provided efficient control of overt or subclinical meningeosis in acute lymphoblastic leukemia (ALL). Especially due to the long-term toxicity of CRT, reduction or elimination of radiother
Publikováno v:
Klinische Padiatrie. 225
During the last 6 years 73 previously untreated children and adolescents with acute lymphoblastic leukemia were enrolled on a non-randomized therapy protocol. In this longitudinal study the specific accent was put on the intensified induction treatme
Publikováno v:
Klinische Pädiatrie. 208:168-171
Thrombopoietin (TPO) belongs to the family of hematopoietic growth factors. It supports the growth and differentiation of megakaryocytic progenitors and precursors in vitro and in vivo. The predominant site of production of TPO is the liver. However,
Autor:
E Greaves, R Allison, V Datton, Archie Bleyer, A Reiter, Harland N. Sather, S Murphy, C P Steuber, M F Auclerc, E C GordonSmith, Indraneel Mittra, Colin Baigent, A Solidoro, M Donnelly, Michael L. Hancock, M Cairo, D Sinclair, E Lepage, P A Shetty, C Harwood, Andrea Pession, R. D. Gelber, T Vietti, A Bancillon, D Mahoney, Richard Peto, V J Land, Santarelli, F SackmanMuriel, Maria Grazia Valsecchi, Giuseppe Masera, Mike Clarke, H Riehm, Richard Gray, C Perez, W Crist, H Duong, Michael E. Trigg, O R McIntyre, J Simone, Ching-Hon Pui, Jon Godwin, Paul S. Gaynon, Julian Peto, L Clavell, Keith Wheatley, J Chessells, Stephen E. Sallan, Martin Schrappe, O B Eden, S Richards, Roberto Rondelli, J Durrant, C Bailey, J Lilleyman, A Burnett, G Schaison, Gregory H. Reaman
Publikováno v:
The Lancet. 347:1783-1788
The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worl
Autor:
A. Reiter, M. Schrappe, E. Yakisan, S. Sauter, W. Ebell, M. Zimmermann, W. Hartmann, B. Kremens, N. Kuhn, A. Claviez, A. Sauerbrey, P. Schmidt, St. Müller-Weihrich, T. Lieber, H. Riehm
Publikováno v:
Klinische Pädiatrie. 206:242-252
The aims of trial NHL-BFM 90 for patients (pts) suffering from B-cell neoplasms are to prove whether: 1. Treatment for pts with complete resection can be reduced from 3 to 2 therapy courses; 2. Results for pts of stage III with large abdominal tumors